What is the latest ABBOTINDIA stock price?
The latest stored price for ABBOTINDIA is Rs 26,230.00 as of 2026-08-21.
gimli
ABBOTINDIA stock AI analysis
ABBOTINDIA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
ABBOTT INDIA LIMITED is a mid-cap stock in Healthcare. This Gimli page shows the latest available ABBOTINDIA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹26,230.00
1W return
-3.07%
1M return
-8.92%
3M return
-5.36%
6M return
-0.25%
1Y return
-19.63%
Market cap
₹55,736.91 cr
PE
35.91
PB
11.67
ROE
+34.46%
ROCE
+44.89%
RSI
34.31
Turnover
₹23.03 cr
Why it can matter in screens
- Momentum: ABBOTINDIA is below 50DMA, below 200DMA; RSI is 34.31.
- Returns: 1D +0.42%, 1W -3.07%, 1M -8.92%, 3M -5.36%, 1Y -19.63%.
- Trend levels: 52W high ₹28,940.00, 52W low ₹25,200.00, off high -9.36%.
- Liquidity: latest turnover is ₹23.03 cr; volume vs 20D is +0.99%.
- Valuation/profitability: PE 35.91, PB 11.67, ROE +34.46%, ROCE +44.89%.
- Growth: 3Y sales CAGR +9.02%, 3Y profit CAGR +17.80%.
Quick Answers
Is ABBOTINDIA above its 50DMA and 200DMA?
ABBOTINDIA is below 50DMA, below 200DMA. The latest 50DMA is 27,023.60 and the latest 200DMA is 27,320.40.
What are ABBOTINDIA PE, ROE and ROCE?
ABBOTINDIA has PE 35.91, ROE +34.46%, and ROCE +44.89% in Gimli's latest available snapshot.
How has ABBOTINDIA performed recently?
ABBOTINDIA has returned -8.92% over 1 month, -5.36% over 3 months, and -19.63% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,709.51 cr | 556.44 cr | 394.93 cr | 185.85 |
| 2025-12-31 | 1,724.04 cr | 533.23 cr | 375.96 cr | 176.92 |
| 2025-09-30 | 1,757.15 cr | 572.12 cr | 415.27 cr | 195.42 |
| 2025-06-30 | 1,738.35 cr | 518.43 cr | 365.86 cr | 172.17 |
| 2025-03-31 | 1,604.59 cr | 504.56 cr | 367.04 cr | 172.72 |
| 2024-12-31 | 1,614.28 cr | 507.84 cr | 360.78 cr | 169.78 |
| 2024-09-30 | 1,632.67 cr | 499.44 cr | 358.61 cr | 168.76 |
| 2024-06-30 | 1,557.61 cr | 458.34 cr | 328.01 cr | 154.36 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 6,929.05 cr | 2,180.22 cr | 1,552.02 cr | 730.36 |
| 2025-03-31 | 6,409.15 cr | 1,970.18 cr | 1,414.44 cr | 665.62 |
| 2024-03-31 | 5,847.19 cr | 1,701.37 cr | 1,201.22 cr | 565.28 |
| 2023-03-31 | 5,346.73 cr | 1,359.78 cr | 949.41 cr | 446.78 |
| 2022-03-31 | 4,996.48 cr | 1,164.93 cr | 798.70 cr | 375.87 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 6,501.93 cr | 442.33 cr | 171.99 cr | 4,774.19 cr |
| 2025-03-31 | 5,917.31 cr | 560.59 cr | 196.67 cr | 4,233.15 cr |
| 2024-03-31 | 5,193.49 cr | 291.74 cr | 83.23 cr | 3,698.89 cr |
| 2023-03-31 | 4,555.51 cr | 239.67 cr | 113.17 cr | 3,188.54 cr |
| 2022-03-31 | 4,224.12 cr | 132.71 cr | 151.69 cr | 2,819.79 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,319.24 cr | 1,278.32 cr | n/a |
| 2025-03-31 | 1,011.84 cr | 959.24 cr | n/a |
| 2024-03-31 | 1,212.81 cr | 1,164.48 cr | n/a |
| 2023-03-31 | 893.39 cr | 859.28 cr | n/a |
| 2022-03-31 | 947.66 cr | 903.59 cr | n/a |
Shareholding Trend
No recent data available.
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze ABBOTT INDIA with valuation, momentum and industry peers
- Compare ABBOTINDIA with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare ABBOTINDIA with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.